Related Experiment Video
Updated: Jan 5, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Dehydrocostus lactone suppresses ox-LDL-induced attachment of monocytes to endothelial cells
Kai Wang1, Aihua Zhou1, Miaohua Ruan1
1Department of Pediatrics, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang Province, China.
Insights
Dehydrocostus lactone (DHL) shows promise in treating atherosclerosis. It inhibits oxidized low-density lipoprotein (ox-LDL)-induced inflammation and monocyte attachment to the endothelium, potentially preventing plaque formation.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Molecular Biology
Background:
- Atherosclerosis is a prevalent cardiovascular disease with complex, poorly understood pathogenesis.
- Endothelial dysfunction, oxidative stress, and inflammation are key contributors to atherogenesis.
- Fatty plaque formation on arterial endothelium is a hallmark of advanced atherosclerosis.
Purpose of the Study:
- To investigate the therapeutic potential of dehydrocostus lactone (DHL) in treating atherosclerosis.
- To elucidate the molecular mechanisms underlying DHL's effects on endothelial cells.
- To evaluate DHL's efficacy against oxidized low-density lipoprotein (ox-LDL)-induced endothelial dysfunction.
Main Methods:
- Assessing DHL's effect on VCAM-1 and E-selectin expression induced by ox-LDL.
- Analyzing downstream effects of VCAM-1 and E-selectin, including monocyte attachment and cytokine release.
- Investigating DHL's impact on KLF2 expression, a regulator of endothelial adhesion molecules.
Main Results:
- DHL significantly inhibited ox-LDL-induced VCAM-1 and E-selectin expression.
- DHL reduced monocyte-to-endothelial cell attachment and the release of proinflammatory cytokines (TNF-α, MCP-1, HMGB1).
- DHL restored the expression of KLF2, an important regulator of endothelial activation.
Conclusions:
- Dehydrocostus lactone (DHL) demonstrates significant potential as a prophylactic or therapeutic agent against atherosclerosis.
- DHL acts by inhibiting ox-LDL-induced endothelial activation and monocyte adhesion.
- DHL's mechanism involves regulating VCAM-1, E-selectin, and KLF2 expression, offering a novel treatment strategy.
Abstract:
Atherosclerosis is a cardiovascular disease that affects most people to at least some extent by old age. Many factors contribute to atherogenesis, and although it is extremely common, the mechanisms behind the pathogenesis of the disease remain poorly understood. Endothelial dysfunction is thought to be one of the main causes of atherosclerosis along with numerous other factors, such as oxidative stress and proinflammatory cytokine upregulation. The culmination of the complications that lead to atherogenesis is the formation of a fatty plaque on the intima of the arterial endothelium. In this study, we explore these aspects and others in regard to the treatment potential of dehydrocostus lactone (DHL), which is naturally occurring in certain flora such as the Saussurea lappa costus plant. Having long been used in traditional Chinese medicine, the effects of this plant are only just beginning to be studied by modern science. Among our most noteworthy findings are that DHL exerts an inhibitory effect against the increased expression of VCAM-1 and E-selectin induced by exposure to oxidized low-density lipoprotein (ox-LDL), which has been linked to the development and progression of atherosclerosis. The introduction of DHL also significantly diminished the downstream effects of VCAM-1 and E-selectin, such as the attachment of monocytes to the endothelium and the release of proinflammatory cytokines and chemokines, including TNF-α, MCP-1, and HMGB1. Furthermore, DHL is capable of rescuing the expression of KLF2, an important regulator of VCAM-1 and E-selectin expression. Together, our findings demonstrate the potential of DHL as a prophylactic or therapeutic treatment against ox-LDL-induced atherosclerosis via inhibition of the attachment of monocytes to endothelial cells.
More Related Videos
Related Concept Videos
Receptor-mediated Endocytosis
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

